Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2A, Open Label, Proof of Concept Trial of Daxdilimab for the Treatment of Moderate To Severe Alopecia Areata

NCT05368103 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT05368103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05368103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2A, Open Label, Proof of Concept Trial of Daxdilimab for the Treatment of Moderate To Severe Alopecia Areata
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
April 27, 2022
Completion date
January 26, 2024
Enrollment
30 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

alopecia areata